Serum tumor markers for screening and early diagnosis of ovarian cancer

1. Guenther J, Stiles A, Champion JD The lived experience of ovarian cancer: a phenomenological approach. J Am Acad Nurse Pract. 2012; 24(10): 595-603.10.1111/j.1745-7599.2012.00732.xSearch in Google Scholar

2. Gentry-Maharaj A, Menon U Screening for ovarian cancer in the general population. Best Practice & Research Clinical Obstetrics & Gynaecology. 2012; 26: 243-256.10.1016/j.bpobgyn.2011.11.006Search in Google Scholar

3. Zhang B, Cai FF, Zhong XY An overview of biomarkers for the ovarian cancer diagnosis. European Journal of Obstetrics and Gynecology. 2011; 158(2): 119-123.10.1016/j.ejogrb.2011.04.023Search in Google Scholar

4. Zang B, Barekati Z, Kohler C, Radpour R, Asadollahi R, Holzgreve W et al. Proteomics and Biomarkers for Ovarian Cancer Diagnosis, Annals of Clinical & Laboratory Science. 2010; 40(3): 218-225.Search in Google Scholar

5. O'Malley D, Azodi M, Makkenchery A, Tangir J, McAlpine J, Kelly M. Serum protein markers for early detection on ovarian cancer. PNAS 2005; 102: 7677-82.10.1073/pnas.0502178102Search in Google Scholar

6. Jacobs IJ, Skates SJ, MacDonald N, Menon V, Rosenthal AN, Davies AP et al. Screening for ovarian cancer: a pilot randomised controlled trial. Lancet 1999; 353: 1207-1210.10.1016/S0140-6736(98)10261-1Search in Google Scholar

7. Moore R G, Maclaughlan S Current clinical use of biomarkers for ovarian cancer. Current opinion in oncology. 09/2010; 22(5):492-7.10.1097/CCO.0b013e32833c335120613519Search in Google Scholar

8. Lu KH, Skates S, Bevers TB, Newland W, Moore RG, Leeds L et al. A prospective US ovarian cancer screening study using the risk of ovarian cancer algorithm (ROCA). J Clin Oncol. 2010; 28:[suppl; abstract 5003]10.1200/jco.2010.28.15_suppl.5003Search in Google Scholar

9. Moore RG, McMeekin DS, Brown AK, DiSilvestro P, Miller MC, Allard WJ et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecologic Oncology. 2009;112: 40-46.10.1016/j.ygyno.2008.08.031359409418851871Search in Google Scholar

10. Mor G, Visintin I, Lai Y, Zhao H, Schwartz P, Rutherford T et al. Serum protein markers for early detection of ovarian cancer. Proc. Natl. Acad. Sci. U.S.A..May 2005; 102(21): 7677-7682.Search in Google Scholar

11. Jacob F, Meier M, Caduff R, Goldstein D, Pochechueva T, Hacker N et al. No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting. Gynecol Oncol. 2011; 121: 487-491.10.1016/j.ygyno.2011.02.02221420727Search in Google Scholar

12. Moore RG, Miller C, DiSilvestro P, et al. Evaluation of the diagnostic accuracy of the risk of ovarian malignancy algorithm in women with a pelvic mass. Obstet Gynecol. 2011; 118(2):280-288.10.1097/AOG.0b013e318224fce2359411021775843Search in Google Scholar

13. ROMA™ (HE4 EIA + ARCHITECT CA 125 IITM) prescribing information. Fujirebio Diagnostics, Inc., 2011.Search in Google Scholar

14. Zhang Z, Bast RC, Yu Y, Li J, Sokoll LJ, Rai AJ et al. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res. Aug 2004; 64(16): 5882-90.Search in Google Scholar

15. Zhang Z, Chan DW Cancer proteomics: In Pursuit of “True”Biomarker Discovery. Cancer Epidemiol Biomarkers Prev. 2005; 14: 2283-2286.10.1158/1055-9965.EPI-05-077416214905Search in Google Scholar

16. Song J, Daniel W, ”Cancer proteomics”. Clinical proteomics. 12/2006; (1542-6416), 2(3): 129.10.1007/BF02752495Search in Google Scholar

17. Hellstrom I, Hellstrom KE SMRP and HE4 as Biomarkers for Ovarian Carcinoma When Used Alone and in Combination with CA125 and/or Each Other. Advances in Experimental Medicine and Biology. 2008;622:15-21.10.1007/978-0-387-68969-2_218546615Search in Google Scholar

18. Hellstrom I, Friedman E, Verch T, Yang Y, Korach J, Jaffar J et al. Antimesothelin antibodies and circulating mesothelin relate to the clinical state in ovarian cancer patients. Cancer Epidemiol Biomarkers Prev. 2008;17:1520-6.10.1158/1055-9965.EPI-08-003918559570Search in Google Scholar

19. Nosov V, Su F, Amneus M, Birrer M, Robins T, Kotlerman J et al. Validation of serum biomarkers for detection of early-stage ovarian cancer. Am J Obstet Gynecol. 2009; 200:63910.1016/j.ajog.2008.12.04219285648Search in Google Scholar

20. Dieplinger H, Ankerst DP, Burges A, Lenhard M, Lingenhel A, Fineder L et al. Afamin and apolipoprotein A-IV: novel protein markers for ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2009; 18: 1127-1133.10.1158/1055-9965.EPI-08-065319336561Search in Google Scholar

21. Zhu CS, Pinsky PF, Cramer DW, Ransohoff DF, Hartge P, Pfeiffer RM et al. A Framework for evaluating biomarkers for early detection: validation of biomarker panels for ovarian cancer. Cancer Prev Res. 2011; 4: 375-383.10.1158/1940-6207.CAPR-10-0193305737221372037Search in Google Scholar

22. Bast RC, Badgwell D, Lu Z, Marquez R, Rosen D, Liu J et al. New tumor markers: CA125 beyound. Int J Gynecol Cancer. 2005; 15: 274-281.10.1111/j.1525-1438.2005.00441.x16343244Search in Google Scholar

23. Moore RG, Brown AK, Miller MC, Skates S, Allard WJ, Verch T et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol. 2008; 108: 402-408. 10.1016/j.ygyno.2007.10.01718061248Search in Google Scholar